FR2799974B1 - Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih - Google Patents

Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih

Info

Publication number
FR2799974B1
FR2799974B1 FR9913549A FR9913549A FR2799974B1 FR 2799974 B1 FR2799974 B1 FR 2799974B1 FR 9913549 A FR9913549 A FR 9913549A FR 9913549 A FR9913549 A FR 9913549A FR 2799974 B1 FR2799974 B1 FR 2799974B1
Authority
FR
France
Prior art keywords
deglycosyl
complex
against hiv
vaccination against
protein env
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9913549A
Other languages
English (en)
Other versions
FR2799974A1 (fr
Inventor
Florence Boudet
Michel Chevalier
Jean Dubayle
Habib Raphaelle El
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Priority to FR9913549A priority Critical patent/FR2799974B1/fr
Priority to AU10327/01A priority patent/AU1032701A/en
Priority to PCT/FR2000/002940 priority patent/WO2001030814A1/fr
Publication of FR2799974A1 publication Critical patent/FR2799974A1/fr
Application granted granted Critical
Publication of FR2799974B1 publication Critical patent/FR2799974B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9913549A 1999-10-25 1999-10-25 Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih Expired - Fee Related FR2799974B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9913549A FR2799974B1 (fr) 1999-10-25 1999-10-25 Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
AU10327/01A AU1032701A (en) 1999-10-25 2000-10-23 Deglycosylated env/cd4 complex and the use thereof for vaccination against hiv
PCT/FR2000/002940 WO2001030814A1 (fr) 1999-10-25 2000-10-23 Complexe deglycosyle env/cd4 et son utilisation pour la vaccination contre le vih

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9913549A FR2799974B1 (fr) 1999-10-25 1999-10-25 Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih

Publications (2)

Publication Number Publication Date
FR2799974A1 FR2799974A1 (fr) 2001-04-27
FR2799974B1 true FR2799974B1 (fr) 2001-11-30

Family

ID=9551513

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9913549A Expired - Fee Related FR2799974B1 (fr) 1999-10-25 1999-10-25 Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih

Country Status (3)

Country Link
AU (1) AU1032701A (fr)
FR (1) FR2799974B1 (fr)
WO (1) WO2001030814A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482744C (fr) 2002-05-07 2013-11-26 Chiron Corporation Complexes et hybrides d'enveloppe vih/cd4
WO2006085959A2 (fr) 2004-06-08 2006-08-17 Novartis Vaccines And Diagnostics Inc. Proteines de fusion comprenant des modules cd4 minimaux, et procedes d'utilisation correspondants
CA2597040A1 (fr) 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics, Inc. Molecules hybrides cd4-tat de vih et methodes d'utilisation connexes
KR20170124619A (ko) 2009-03-27 2017-11-10 아카데미아 시니카 바이러스에 대한 면역을 위한 방법 및 조성물
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005799A1 (fr) * 1990-09-28 1992-04-16 Hospital For Joint Diseases Procede inhibant l'action infectieuse du virus de l'immunodeficience humaine
ES2166779T3 (es) * 1993-05-07 2002-05-01 Bio Merieux Inc Complejos inmunogenicos del hiv.

Also Published As

Publication number Publication date
AU1032701A (en) 2001-05-08
FR2799974A1 (fr) 2001-04-27
WO2001030814A1 (fr) 2001-05-03

Similar Documents

Publication Publication Date Title
NO20031843L (no) Metylfenidatmodifiserte frigjöringspreparater
DK1015596T3 (da) Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner
NO20015278L (no) 6-alkenyl-, 6-alkynyl- og 6-epoksy-epotilonderivater, fremgangsmåte for deres fremstilling og deres anvendelse ifarmasöytiske preparater
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
AU8499901A (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
EE200200038A (et) Konservitud farmatseutilised preparaadid
ZA200602858B (en) HIV vaccines based on Env of multiple clades of HIF
FR2811220B1 (fr) Prothese active modulaire pour bras et avant-bras
DE60029306D1 (de) Zusammenlegbarer behälter und zugehörige verbindungsvorrichtung
TR200100054T2 (tr) Paroksetin metansülfonat
DE60018800D1 (de) Lösliche druckempfindliche klebmittel
FR2799974B1 (fr) Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
AU2001288061A1 (en) Drug resistance-associated gene and use thereof
AU2002255642A1 (en) Sulfated ccr5 peptides for hiv-1 infection
NO20022022L (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20034524L (no) 5-leddete heterocykler, fremstilling og anvendelse derav som MAO inhibitorer og lipidperoksidasjonsinhibitorer, fremstilling derav oganvendelse derav sommedikamenter
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
FR2796073B1 (fr) Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
FR2828687B1 (fr) Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.
DK1183241T3 (da) Spiroimidazolidinderivater, deres præparation, deres anvendelse og farmaceutiske præparationer omfattende disse
AU7537100A (en) Assaying in vivo t-cell response upon dna vaccination
AU2002314549A1 (en) Transgenic animals and cells expressing proteins necessary for susceptibility to hiv infection
DE29902695U1 (de) Krankenhebevorrichtung
AU2002355653A1 (en) Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
CD Change of name or company name
ST Notification of lapse

Effective date: 20090630